<--- Back to Details
First PageDocument Content
Health / Pharmacology / Gynaecological cancer / Drug safety / Cervarix / HPV vaccine / Human papillomavirus / Cervical cancer / Food and Drug Administration / Papillomavirus / Medicine / Vaccines
Health
Pharmacology
Gynaecological cancer
Drug safety
Cervarix
HPV vaccine
Human papillomavirus
Cervical cancer
Food and Drug Administration
Papillomavirus
Medicine
Vaccines

Cervarix Pediatric Safety and Utilization Rev iew

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 210,16 KB

Share Document on Facebook

Similar Documents

Cancer / Clinical medicine / Health / Infectious causes of cancer / Papillomavirus / RTT / Gynaecological cancer / Vaccines / Human papillomavirus infection / HPV vaccines / Gardasil / Wart

INTRODUCTION Anogenital human papillomavirus (HPV) infections are nearly ubiquitous among sexually active individuals: data indicate that up to 80% of sexually active persons experience one or more anogenital HPV infect

DocID: 1rtdm - View Document

RTT / Gynaecological cancer / Gynaecology / Ovarian cancer

Elvira Ann Marano August 20, October 27, 2010

DocID: 1rpU4 - View Document

Cancer / RTT / Health / Clinical medicine / Infectious causes of cancer / Papillomavirus / Gynaecological cancer / Carcinogens / Human papillomavirus infection / Cervix / N.E.D. / Ovarian cancer

PDF Document

DocID: 1rmwK - View Document

Medicine / Clinical medicine / Cancer / RTT / Infectious causes of cancer / Cancer screening / Gynaecological cancer / Sexually transmitted diseases and infections / Cervical cancer / Fecal occult blood / Preventive healthcare / HPV vaccines

Be Healthy Wellness Benefits Be Healthy–

DocID: 1rifu - View Document

Cancer / Clinical medicine / Health / Infectious causes of cancer / RTT / Papillomavirus / Gynaecological cancer / Vaccines / Cervical cancer / HPV vaccines / Human papillomavirus infection / Cancer screening

Invited Speaker Seminar Title: Combining decision modeling and epidemiologic studies to determine optimal cervical cancer control policies in the era of HPV vaccines. Speaker: Shalini Kulasingam, PhD Host: Prof David Mat

DocID: 1re0N - View Document